MNIVF
Monash IVF Group Limited engages in the provision of assisted reproductive and specialist women imaging services in Australia and Malaysia. It offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. It also provides tertiary level prenatal diagnostic, and IVF treatment services. Monash IVF Group Limited was incorporated in 2014 and is headquartered in Richmond, Au… Read more
MNIVF (MNIVF) - Net Assets
Latest net assets as of June 2024: $254.84 Million USD
Based on the latest financial reports, MNIVF (MNIVF) has net assets worth $254.84 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($516.65 Million) and total liabilities ($261.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $254.84 Million |
| % of Total Assets | 49.33% |
| Annual Growth Rate | -2.84% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.44 |
MNIVF - Net Assets Trend (2021–2024)
This chart illustrates how MNIVF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MNIVF (2021–2024)
The table below shows the annual net assets of MNIVF from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | $246.66 Million | -10.33% |
| 2023-06-30 | $275.07 Million | +1.92% |
| 2022-06-30 | $269.89 Million | +0.36% |
| 2021-06-30 | $268.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MNIVF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $404.64 Million | 167.27% |
| Total Equity | $241.91 Million | 100.00% |
MNIVF Competitors by Market Cap
The table below lists competitors of MNIVF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ValueHD Corp. A
SHE:301318
|
$155.90 Million |
|
JIUMAOJIU INTL HLDGS LTD
F:3YU
|
$155.96 Million |
|
WW International, Inc. Common Stock
NASDAQ:WW
|
$155.99 Million |
|
Yeahka Limited
PINK:YHEKF
|
$156.00 Million |
|
Greaves Cotton Limited
NSE:GREAVESCOT
|
$155.84 Million |
|
Subros Limited
NSE:SUBROS
|
$155.83 Million |
|
Astra Otoparts Tbk
JK:AUTO
|
$155.83 Million |
|
AzureWave Technologies Inc
TW:3694
|
$155.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MNIVF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 273,201,000 to 241,905,000, a change of -31,296,000 (-11.5%).
- Net loss of 6,527,000 reduced equity.
- Dividend payments of 18,323,000 reduced retained earnings.
- Other factors decreased equity by 6,446,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.53 Million | -2.7% |
| Dividends Paid | $18.32 Million | -7.57% |
| Other Changes | $-6.45 Million | -2.66% |
| Total Change | $- | -11.46% |
Book Value vs Market Value Analysis
This analysis compares MNIVF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.08x to 1.19x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | $0.68 | $0.74 | x |
| 2022-06-30 | $0.69 | $0.74 | x |
| 2023-06-30 | $0.70 | $0.74 | x |
| 2024-06-30 | $0.62 | $0.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MNIVF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.56%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 2.10x
- Recent ROE (-2.70%) is below the historical average (5.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 9.43% | 13.70% | 0.52x | 1.32x | $-1.52 Million |
| 2022 | 6.87% | 9.57% | 0.50x | 1.42x | $-8.39 Million |
| 2023 | 7.99% | 10.22% | 0.51x | 1.54x | $-5.48 Million |
| 2024 | -2.70% | -2.56% | 0.50x | 2.10x | $-30.72 Million |
Industry Comparison
This section compares MNIVF's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MNIVF (MNIVF) | $254.84 Million | 9.43% | 1.03x | $155.85 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |